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Executive Summary  
Abstract 
 Over the past several decades the World Health Organization (WHO) has produced the 
Essential Medicines List (EML) to assist countries in deciding what medicines should be 
essential and available in National Essential Medicine Lists.1 WHO, through the work of regional 
offices, supports nations using the EML to ensure the quality, availability, and affordability of 
pharmaceuticals required to promote and advance public health in nations across the globe. 
However in some cases, access to EML pharmaceuticals might be complicated by existing 
patents, i.e., where issued, patent rights might pose obstacles to access and inclusion in 
national EMLs. Indeed, in developed and emerging economy national jurisdictions patent 
protection may be in effect for a not insignificant number of the WHO EML pharmaceuticals 
(Figure 2A). However, in developing countries, it is uncertain whether these patents have been 
filed or issued. Without patent data predicated on an established, reproducible protocol for 
accessing and assembling patent information on the EML pharmaceuticals, discussions, 
debates and strategic approaches to understanding and managing patents with regard to 
access and delivery to developing countries remain in the dark. Indeed, it is absurd to make 
policy and formulate strategy without solid patent information: the critical foundation for 
rational debate.  
 To analyze the degree and scope of patenting of EML pharmaceuticals, WIPO (with WHO) 
approached the Franklin Pierce Center for Intellectual Property at the University of New 
Hampshire School of Law, specifically the International Technology Transfer Institute (ITTI) to 
generate a preliminary overview of patents appurtenant to recently added pharmaceutical 
updates to the EML.2 As part of this work, with inputs from WHO and WIPO, ITTI developed 
novel methodology and a detailed protocol for identifying EML pharmaceutical patents in 
national jurisdictions, with an easily reproducible yet cost effective template. Herein is 
described the development of such a protocol and a preliminary pool of patent information that 
illustrates its utility. The protocol yields data in a layered approach thereby allowing a user to 
quickly and effectively obtain both broad and detailed patent information for medications on 
the WHO EML. In addition, the protocol can be used as an initial path for targeted strategic 
analysis of potentially relevant patent information in national jurisdictions.  
 
In sum, the objectives for this project were: 
1. To develop a robust methodology to assess the patent status of medicines on the WHO 
Model List of Essential Medicines; 
2. To place in the public domain a detailed report on the present (2010) patent status of 
medicines that were on patent in 2003 and those medicines added to the Model List 
since 2003 by country and level of development; and 
3. To analyze the patent status of these Essential Medicines by the development status of 
countries.  
 
 The report describes the development of the protocol and presents a preliminary list of 
EML and corresponding patents in certain jurisdictions to illustrate the utility of the approach. 
Results will be discussed both in terms of global access and patents, and in the context of 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  1	  WORLD	  HEALTH	  ORGANIZATION,	  CONTINUITY	  AND	  CHANGE	  IMPLEMENTING	  THE	  THIRD	  WHO	  MEDICINES	  STRATEGY	  2008-­‐2013	  20	  (WHO	  Press,	  3rd	  ed.	  2009).	  2	  This	  report	  covers	  the	  EML	  up	  to	  and	  including	  updates	  until	  2009.	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establishing standard, systematic, protocols for periodic patent searches related to EML 
content. 
EML Purpose, Policy, and Evolution 
 Through extensive collaboration with regional offices, WHO supports the development, 
implementation, and monitoring of the effectiveness of national medicinal guidelines to ensure 
the quality, availability, and affordability of medications effective against a broad range of 
indications.3 WHO released the first of these guidelines, the EML, in 1977 to address the many 
problems faced by nations attempting to develop individualized national lists.4 
 Over time WHO has needed to continually update the EML, along with its efforts to 
implement national policies for pharmaceutical availability. The privatization of most 
pharmaceutical discovery and manufacture, along with an increase in patenting in both the 
public and private research and development sectors, has led to a patenting activity of 
medications in many national jurisdictions. This, in turn, creates challenges for WHO to 
continually monitor and appraise the patent status of EML pharmaceuticals within the context 
of potentially relevant and enforceable patent rights in any given national jurisdiction. A 
system/protocol that permits patent information to be reproducibly mined and analyzed will 
facilitate the ongoing process of ascertaining global access.  
EML criteria selection and current list 
 Medications listed on the EML are those that satisfy the priority health care needs of the 
nation, with respect to the prevalence of particular disease states, while maintaining a level of 
efficacy, safety, and reasonable cost effectiveness.5 The EML is not designed as the only 
available list nor is it designed as a global standard.6 Rather, the EML is designed to promote 
the concept of essential medicines to establish health equity in a given nation.7 The current 
EML provides a listing of medications for a variety of disease states from relatively simple to 
considerably more complex preparations, such as vitamins that reduce nutritional deficiencies 
to the latest HIV/AIDS medications.8 The EML is sufficiently broad that when used together, the 
medications provide safe and effective treatment for the majority of communicable and non-
communicable diseases.9  
 As some of these medicines are relatively new and thus may lack generic equivalents, 
potential patent rights in some national jurisdictions might condition availability of some 
medicines on the EML. With patent protection existing for some of the EML pharmaceuticals, 
WHO recognizes it is important that countries placing these medicines into National lists be 
aware of local and global patenting activities.10 However, undertaking such research can be an 
onerous task and can also fail to identify with 100% certainty the current patent protection of 
medications on the EML in any given national jurisdiction. The latest EML contains a broad 
range of medications, making verification of patent protection for each medication in this report 
difficult.  
 By employing a combination of patent search approaches, the method outlined herein 
seeks to establish the basis for an effective search methodology for patents covering EML 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3	  THE	  SELECTION	  AND	  USE	  OF	  ESSENTIAL	  MEDICINES	  -­‐	  WHO	  TECHNICAL	  REPORT	  SERIES,	  NO.	  914	  (WHO	  Press,	  2002).	  4	  Id.	  	  5	  Continuity	  and	  Change,	  supra	  29.	  6	  Id.	  at	  19-­‐20.	  7	  Id.	  8	  World	  Health	  Organization,	  WHO	  Model	  List	  of	  Essential	  Medicines	  (WHO	  Press,	  16th	  ed.	  2009).	  9	  Id.	  10	  Continuity	  and	  Change,	  supra	  24-­‐25.	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pharmaceuticals. It is hoped, and indeed anticipated, that this will then serve as a launching 
point for further refinements and application of patent searching and analyses as a basis for 
policy formulation and assessment of strategic options to facilitate access to EML 
pharmaceuticals in all countries across the globe.  
Methodology 
 Previous analyses to gauge patent protection for medications on the EML demonstrated 
that the breadth and scope of searching necessary for accuracy presented a challenge.11 
Ultimately, this complexity necessitated approaching pharmaceutical companies to obtain 
individual patent portfolios to identify patent protections for medications listed on the EML.12 
Such a methodology was the approach of Dr. Amir Attaran and colleagues in 2003,13 who 
surveyed 319 products on the WHO EML to identify the subset recent enough to still be 
subject to patent protection at that time.14 Initially searching several pharmaceutical patent 
reference sources for each specific product on the WHO EML, they identified the earliest U.S. 
patent for the EML pharmaceuticals or their combinations.15 They subsequently searched two 
commercial patent databases, (INPADOC and Derwent WPI) which yielded preliminary 
international patent data, followed by written surveys to the manufacturer of each product to 
further ascertain and elucidate global patent coverage for each EML pharmaceutical.16  
 While similar, the ITTI approach differed in several key respects from that of the Attaran 
group’s methodology. The goal was to develop a comprehensive yet readily transferrable 
methodology to identify patent filings for medications on the WHO EML. Creating such a 
protocol required use of both free and fee-based, value-added patent searching tools and 
platforms, along with the development of in-house value-added resources. While the concept 
is fundamental, identifying base patents and FDA Orange Book listings for each medication on 
the EML and their corresponding global filing trends (in practice, obtaining comprehensive 
results) is complex, ultimately requiring iterative rounds of additional searching and analysis.17 
ITTI-developed methodology was designed to initially locate base patents for each medication, 
via a platform capable of facilitating more in-depth and complex patent searches for EML 
pharmaceuticals. Hence, assessing actual patenting activity in the EML should be viewed as a 
tiered, stepwise process, with the results and protocol presented herein as an initial gateway 
into the field of global patenting activity.  
 As a consequence, ITTI focused on generating a preliminary list of potentially relevant 
patent literature and a preliminary methodology applicable to a more general audience, to both 
illustrate how to manage patent information appurtenant to the EML and to present a sample 
data set. The methodology thus serves as a guide to patent trends rather than as a 
methodology for locating all available patents for a given medication. However, the report still 
is capable of leading a user to the more complex stage of searching as articulated throughout. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  11	  Amir	  Attaran,	  How	  Do	  Patents	  and	  Economic	  Policies	  Affect	  Access	  to	  Essential	  Medicines	  in	  Developing	  Countries?	  23(3),	  Health	  Affairs,	  155.	  12	  Id.	  at	  156-­‐57.	  13	  Id.	  at	  155.	  14	  Id.	  at	  156.	  15	  Id.	  16	  Id.	  at	  157	  17	  91	  medicines	  were	  assigned	  to	  ITTI	  for	  this	  study.	  70	  base	  patents	  were	  identified	  along	  with	  152	  listed	  patents	  within	  the	  FDA	  Orange	  Book.	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Figure	  1:	  Flowchart	  for	  Results	  and	  How	  the	  Data	  was	  Generated	  for	  this	  Report.	  91	  total	  medicines	  were	  reduced	  to	  78	  after	  removing	  products	  that	  likely	  did	  not	  have	  existing	  patent	  coverage	  because	  of	  the	  age	  of	  the	  drug	  or	  because	  they	  were	  not	  singly	  patentable	  products.	  From	  the	  78	  investigated	  medicines,	  70	  base	  patents	  and	  152	  orange	  book	  patents	  were	  obtained	  that	  were	  reduced	  to	  166	  unique	  documents	  after	  removing	  redundancies.	  The	  166	  unique	  documents	  were	  expanded	  using	  family	  data	  to	  27568	  patent	  documents. 
  Using this protocol, ITTI located base patents and FDA Orange Book Patents, totaling 166 
unique patents, for nearly every medication on the EML updates since 2003, to provide a 
snapshot of relative patent filings currently in 2010 while also guiding a user to more complex 
searching strategies.18  
Preliminary Results: Global Patent Filing for EML Pharmaceuticals  
 Assembling and organizing data from the identified patents into patent families and 
displaying this information on world (geographical) maps provides an overview of global patent 
filing trends for EML pharmaceuticals. These data, expanded to encompass all of the nations 
where a family had, at least, been filed for one medication from the EML (Figure 2), suggests 
that nations with developed economies, established health programs and resources have 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  18	  ITTI	  defines	  unique	  patents	  as	  patents	  that	  may	  exist	  for	  multiple	  medicines	  but	  are	  only	  listed	  once	  for	  more	  in-­‐depth	  analysis.	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greater patenting activity for EML pharmaceuticals. In contrast, developing countries lacking 
adequate health programs or having little resources appear to have a dearth of patent filings in 
their jurisdictions. This is perhaps not surprising, and not inconsistent with the overall 
observations of the Attaran group.19 
 Thus generally, developed country jurisdictions like, North America, Australia and Europe, 
as well as emerging economies such as China, India and Brazil appear to have higher levels of 
patent filing for many of the EML pharmaceuticals. In contrast, much of South America, Africa, 
and the Middle East, i.e., developing economies, appear to have little to no patent filing activity 
for the EML pharmaceuticals. This apparent lack of patent protection, while seemingly 
beneficial for eliminating potential infringement concerns, instead may actually require more in 
depth analyses in order to ascertain the true patenting situation in these countries, as their 
patent data may not be reliably reported, or available, in conventional patent search databases 
and platforms. However, it is crucial to note that an actual, and verified, absence of patents in 
these countries could facilitate a way for WHO/WIPO to create new healthcare plans and 
establish generic-based National EMLs with broad coverage of the EML. The methodology 
presented herein, along with the preliminary results, provides a step towards making such 
informed determinations.  
 It must be duly noted that applications were identified for the regional patenting authorities, 
such as WIPO, EPO and ARIPO. These applications might have patent filings in many nations 
not colored on the global maps, and might therefore provide additional national jurisdictional 








	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  19	  Amir	  Attaran,	  supra	  163.	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Figure 2: Number EML Medicines Patented or Pending in National Jurisdictions. Consolidation of a total of 
27568 patents identified for medications on the EML and its related family members. 166 unique patents identified 
using the ITTI Clinic’s approach were subjected to family data analysis using INPADOC, DWPI, and LexisNexis® 
TotalPatentTM generating a total of 27568 patents in multiple families. The patents were de-duplicated prior to 
consolidation. A) Number of medicines patented per jurisdiction for all years. Regional office filings were detected: 
ARIPO=15, OAPI=17, EAPO=13, EPO=41, WIPO=30. B) Number of medicines patented per jurisdiction post 1990. 
Regional office filings were detected: ARIPO=14, OAPI=11, EAPO=14, EPO=34, WIPO=30. 
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Patent Filing and Income Level 
 To assess the global filing trends of the EML pharmaceutical patentees, patent families 
were analyzed and compiled in developed and developing country jurisdictions. Figure 3 
shows the compilation of those data. Interestingly, and consistent with Figure 3, the majority of 
patent filing activity for EML pharmaceuticals appears to be in higher income rather than lower 
income nations (see Figure 3). The disparity between filings in higher income nations and lower 
income nations is not inconsistent with the general principle, as elucidated by Attaran, that 
patentees file in national jurisdictions where the markets are developed to the point where 
patent protection makes economic sense; in other words, as the economy develops, so do 
markets with patenting following as markets mature. 
Figure 3: Essential Medicines and Their Relationship to World Bank National Income Levels – Post 1990. Data 
is cumulative of patent filings arising from Base Patents, Orange Book Patents, and Family Patents. The number of 
medicines represents the combined total number of patent filings in each country (representative medicines in the 
graph are from a binary analysis. That is a 1 designates if any patent document is filed in a particular jurisdiction, 
therefore counting the medicine as patented in that income level, and a 0 designates if no patent documents are 
filed in a particular jurisdiction). A medicine patented in multiple countries was counted a single time regardless of 
the number of jurisdictions the medicine was patented. Income levels are derived from World Bank. 
 
 Similar disparity can be seen between organizations like the EPO and ARIPO (See Figure 2 
legend).20 The EPO has considerable more patent filings than ARIPO, suggesting that many 
EML pharmaceutical patentees do not seek protection in Africa other than a few nations, for 
example South Africa.  
 Lastly, analyzing the current assignees to the unique 166 patents identified as either base 
patents or Orange Book patents reveals that three dominant companies; Abbott, Merck, and 
GSK appear to actively and aggressively pursue patent rights for their medicines (see Figure 3). 
Companies shown in Figure 3 should be approached to discuss patents and other protections 
for their medicines listed on the EML. 
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Figure 4: Comparison of Assignee Companies. Assignees were determined from the 166 unique patent 
documents found on the Master Patent Spreadsheet. 
Caveats 
 While the overall data suggest that the prevailing trend for filing of patent applications for 
EML pharmaceuticals has been in countries with developed economies, established healthcare 
plans and market potential for pharmaceuticals, caution should temper hasty conclusions vis-
à-vis patent protection in countries outside of the developed and industrialized categories. 
Countries with apparent lack of patent filing activity should not automatically be discounted as 
countries EML pharmaceutical patentees ignore for patent protection.  
 There are several reasons for caution. First, as the data presented herein suggests, global 
patent filing trends for EML pharmaceuticals appear to be correlated with emerging 
economies. Hence, countries that might not have been considered as filing jurisdictions in 
1995, e.g., Brazil, India and China, are now increasingly jurisdictions wherein patent protection 
is sought. Assuming that this global economic development extends into the 21st century, 
additional national jurisdictions will likely also become attractive for filing. Hence, ascertaining 
likely filing jurisdictions needs to be conditioned on the dynamism of global development and, 
if recent trends are indicative, there will be a gradual increase in both the amount and global 
distribution of patent filings.  
 Second, many national jurisdiction patent filing authorities have likely not yet made their 
complete patent information available through web-based and electronic resources, amenable 
to patent searching tools and platforms. Theoretically, such jurisdictions may have patent 
protection for EML pharmaceuticals that is not readily detectable. In other words, electronic 
patent searching cannot locate documents from these jurisdictions. Further, there are many 
national jurisdictions that are not yet included in the patent family databases used to assemble 
data, e.g., INPADOC, Derwent and Lexis Total Patent (as used in this report).21 And even when 
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national jurisdiction might be slow, incomplete or incorrect. Hence, as stated already, when 
carefully considering the freedom to operate (FTO) status in a national jurisdiction, the more 
conservative/methodical/standard approach to consult with patent professionals in said 
jurisdiction and/or regional patent offices to identify potential patents should be carefully 
considered.22 
 Finally, any patent search strategy is limited by the very parameters that yield results. 
For example, both the ITTI and the Attaran protocols have strengths and weaknesses that 
must be weighed against efficiency and precision. The ITTI protocol was largely based on 
Orange Book information, which derives from U.S. patent filings and is also only a restricted 
data set based upon FDA approval and innovator filed information. Whereas the 
disproportionate number of patentees for EML pharmaceuticals file in the U.S., an increasingly 
large number of emerging economy entities may begin to seek patent rights; if these entities do 
not file U.S. patent applications on relevant EML pharmaceuticals, then they could fall outside 
of the search parameters of this report. Similarly, the Attaran protocol relied on data supplied 
by top assignees, which, although providing highly useful information on patent filing in 
developing countries, could also possibly miss other, perhaps more recent, EML 
pharmaceutical patentees, particularly those filing patents solely in national offices, e.g., India, 
China and Brazil.  
Conclusions and Key Implications 
 EML medicines, intended to be available in functioning health systems in all countries, are 
among the most cost-effective ways to treat infectious (e.g., respiratory infections, diarrhea, 
tuberculosis, malaria, AIDS) and chronic (e.g., asthma, cancer, diabetes) diseases in 
developing countries.23 Yet, availability of EML medicines is hampered by poor supply and 
distribution systems, insufficient health facilities and staff, low investment in health, and high 
cost (particularly in developing countries where pharmaceuticals can literally consume 
household finances to the point of poverty).  
 Whether patents have complicated the efforts of WHO to implement its global EML agenda 
is an issue that has been the subject of discussion and debate. However, informed discussion 
and debate will be facilitated when the existence and/or extent of such potential patent 
complications is quantified and thereby better understood with empirical data. This report 
provides WHO with both representative data and a preliminary protocol for assessing global 
patenting with regard to additions to the EML.  
 Key implications of this report include: 
• A standardized protocol is a critical tool for periodic identification and analyses of 
patents appurtenant to updates of the WHO EML. Said protocol should be made 
available, and indeed taught to, all Member States, with particular focus on the 
developing nations.  
• Of the 91 medicines evaluated, 74 were added to the EML since 2003, and 17 were 
previously identified by Attaran in his 2004 paper. A total of 17 were identified from the 
evaluated list as possibly still being under patent protection in different jurisdictions, 
including in several developing countries.  
• Caution in assessing FTO in any given jurisdiction should be the modus operandi; a 
stepwise approach which proceeds from a standardized protocol to more diligent 
research, e.g., analyzing patentee portfolios or in-country paper-based patent searches, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  22	  See	  Appendix	  D	  for	  a	  full	  country	  coverage	  list	  of	  the	  three	  patent	  databases	  (INPADOC,	  DWPI,	  TotalPatent)	  used	  in	  this	  report.	  23	  Model	  List	  of	  Essential	  Medicines,	  supra	  14-­‐15.	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is strongly recommended. Hasty assumptions based on preliminary data are neither 
judicious nor prudent.  
• Data presented in the ITTI EML patent study support the proposition that global 
patenting trends follow economic development and markets; this is a dynamic and fluid 
situation across the world; patentees will likely file patent applications in more countries 
as viable economic markets expand accordingly.  
• Patents per se might not be a primary obstacle for access to EML pharmaceuticals in 
many developing countries, as they are consistently not detected in patent family data 
from developing nations and regions; yet caution in assessing FTO is always necessary.  
• More recent EML pharmaceuticals appear to have greater global patent filings, which is 
not inconsistent with generally increasing global trends in patenting activity.  
 
In conclusion, debates and discussion on patents and access to EML pharmaceuticals 
needs to be based on empirical data, otherwise they will likely continue in circles, dominated 
by ideology sans evidence. 
 
 
Part I, Pages 1 - 50 Executive Summary, Introduction, Methods, Results, and Discussion Sections.
	   1	  
Disclaimer and Scope of Project 
 This is solely an educational report and is neither inclusive nor comprehensive. The 
information provided in this report serves as a resource for initiating a search strategy aimed at 
providing a survey of relevant patent literature with regard to medicines listed on the WHO 
Essential Medicines List. This report is not a freedom-to-operate opinion (FTO), and the 
International Technology Transfer Institute (ITTI) Clinic at the Franklin Pierce Center for 
Intellectual Property (FPCIP) at the University of New Hampshire School of Law (UNH-Law) 
draws no conclusions, makes no opinions or representations either explicitly or implicitly, 
including but not limited to patent term and expiration dates, and geographic coverage. 
 Neither the ITTI Clinic nor UNH-Law are responsible for any errors, omissions, and 
limitations of data or search parameters of any data source used within this report. The patent 
searching platforms utilized in this report are limited to English language searching of full text 
patent documents and abstracts using machine translated national and bibliographic records 
including but not limited to those arising from DWPI and INPADOC.  
 Neither the ITTI Clinic nor UNH-Law are experts in the field of pharmaceutical patent law. 
Therefore no guarantees or opinions are expressed herein with respect to the evaluation of 
patents as ITTI Clinic members did not perform claim interpretation or determine the validity of 
claims. The tight time frame for report preparation, overall demands faced by the ITTI Clinic 
Student Team, and limitations imposed by both the search methodology and patent search 
platforms used affected the level of sophistication and the number of patents found and 
evaluated. As such, additional patents whether inside or outside the confines of the 
methodology herein, were not considered. The ITTI Clinic also aware of the now available 
online ARV database provided by Medicines Patent Pool Foundation in collaboration with 
WIPO.24 This database became available after the data for this report was generated and 
therefore was not used in the methodology in this report. 
 The confines of the methodology used in this report limit the data to medicines having a US 
patent or US patent application either as the parent document or within a base patent family 
and is limited to updates to the EML between 2003 and 2009. Medicines lacking a US Patent 
or US Patent Application remain unidentified by all searches performed in this report. Finally, 
with regard to any national or regional jurisdiction patent filing, whether within or outside of the 
defined scope of this project, it is imperative to appreciate the difficulties of locating patents in 
national jurisdictions that do not report, or report infrequently, to electronic or internet patent 
databases. All users of this report should engage a patent professional in all jurisdictions of 
interest to evaluate any patents listed within this report. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  24	  The	  Patent	  Status	  Database	  for	  Selected	  HIV	  Medicines.	  (Accessed	  May	  22,	  2011.)	  http://www.medicinespatentpool.org/LICENSING/Patent-­‐Status-­‐of-­‐ARVs.	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Abbreviations 
 
AIDS: Acquired Immune Deficiency Syndrome 
ANDA:  Abbreviated New Medicine Application 
ARIPO: African Regional Intellectual Property Authority 
ARV: Anti-retroviral medicine 
Base Patent: Earliest identified patent for the active pharmaceutical ingredient, 
formulation, or method of use 
CAS: Chemical Abstract Service 
DTP: Decision Tree Protocol 
DWPI: Derwent World Patent Database 
EAPO: Eurasian Patent Organization 
EFV: Efavirenz 
EPIDSD: European Patent Information Documentation Systems Directorate 
EPO: European Patent Organization 
EPC: European Patent Convention 
Exclusivity:  Exclusive marketing right granted and valid in the US by the FDA 
upon approval of a medicine product 
FDA:  United States Food and Drug Administration 
FTC: Emtricitabine 
GCC: Gulf Cooperation Council 
HIV: Human Immunodeficiency Virus 
ITTI Clinic: International Technology Transfer Institute | Franklin Pierce 
Center for Intellectual Property | University of New Hampshire 
School of Law 
INPADOC:  International Patent Document 
IUPAC:  International Union of Pure and Applied Chemistry 
EML: Model List of Essential Medicines 
NCE: New Chemical Entity 
NDA: New Medicine Application 
OAPI/AIPO: Organisation Africaine de la Propriété Intellectuelle/African 
Intellectual Property Organization 
OB: FDA Orange Book 
ODE: Orphan Medicine Exclusivity 
PAIR:  Patent Application Information Retrieval 
PCE: Patent Challenge Exclusivity 
PCT: Patent Cooperation Treaty  
PED: Pediatric Exclusivity 
PUC: Patent Use Code 
TDF: Tenofovir Disproxol Fumarate 
USPTO: United States Patent and Trademark Office  
WIPO:  World Intellectual Property Organization  
WHO: World Health Organization 
WTO: World Trade Organization 
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Introduction 
WHO Essential Medicines List (EML) Background 
 The World Health Organization (WHO) is the directing and coordinating authority for health 
within the United Nations. It is responsible for providing leadership on global health matters, 
shaping the health research agenda, setting norms and standards, articulating evidence-based 
policy options, providing technical support to countries, and monitoring and assessing health 
trends. In 1975, WHO was commissioned with the task of identifying a list of medicines that 
were “of the utmost importance, basic, indispensable, and necessary for the health and needs 
of the population.” The first list identified 205 medicines that were selected after consideration 
of safety, quality, efficacy, and total cost.25 The goal of the initial list was to provide guidelines 
for the rational use of pharmaceuticals, both in the developed and developing world, by 
establishing a principle that some medicines were more essential than others to meet the 
needs of the population.26 That principle quickly gained global favor, resulting in shift beyond 
mere selection of drugs to a list that is beneficial to procurement, distribution, and quality 
assurance.  
 Today, WHO continues to develop the Essential Medicines List (EML), releasing new 
guidelines approximately every two years.27 While the list has remained structurally unchanged, 
the definition of what constitutes an essential medicine has evolved.28 WHO now defines 
essential medicines as medicines that satisfy the priority health care needs of the population.29 
Each medicine is selected with due regard to public health relevance, evidence of efficacy and 
safety, and comparative cost-effectiveness. Essential medicines are intended to be available 
within the context of functioning health systems at all times, in adequate amounts, in the 
appropriate dosage forms with assured quality and adequate information, and at a price the 
individual and the community can afford.30 
 The EML consists of two categories, the core medicines and the supplemental medicines.31 
The core medicines are essential medicines that meet the selection criteria by being 
efficacious, safe, and cost effective.32 In contrast, the supplemental medicines, while still 
satisfying the healthcare needs of the population, do not meet all the selection criteria and are 
typically costly or require specialized facilities or services for administration.33 Though the EML 
guidelines propagated to assist national procurement offices contain the entire set of core 
medicines, the supplemental medicines should not be overlooked for inclusion on national lists. 
 The EML began as a selection of medicines by WHO programme staff and expert 
committees who used little to no evidence to support inclusion of medicines on the EML.34 In 
response to the growing need to provide support for the choices on the list, today, an 
evidence-based approach is now used that provides support for each of the selection criteria 
for inclusion of the medicine on the list.35 What began as an idea to advocate the essentiality of 
particular medicines has now blossomed into a vital tool for implementing the procurement and 
distribution of pharmaceuticals to developing countries. 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  25	  Lancet	  1991;	  338,	  743-­‐45.	  26	  Id.	  27	  Lancet	  2003;	  361,	  1723-­‐29.	  28	  Id.	  29	  Id.	  30	  Id.	  31	  Id.	  32	  Id.	  33	  Id.	  34	  Lancet	  2003,	  361,	  1723-­‐29.	  35	  Id.	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 The EML is intended to serve as a guide to national procurement officers in establishing 
national lists unique to the needs of each specific jurisdiction.36 Essential medicines are 
intended to be flexible and adaptable to many different situations and exactly which medicines 
are regarded as essential remains a national responsibility. Thus some differences between the 
WHO EML and national lists are present and expected.37 The EML is designed as a broad-
spectrum solution to aid in determining essential medicines for the majority of disease 
indications. However, because every nation’s needs and morbidity patterns differ, inclusion 
and deletion of medicines on the national list with respect to the needs of its population is 
justified.38  
Since its development in 1975, the EML has guided the interpretation of national lists and 
medicines essential for maintaining a healthy population. Its popularity as a guideline for 
countries to establish their own lists is universal as virtually every country has some form of a 
national list. This report focuses solely on the WHO EML and does not consider national lists in 
any respect. 
Previous Work 
 The growing concern about safeguarding patent protection of medicines on the EML has 
been at the forefront of national procurement offices for many years. Since the EML serves as 
the guide to many nations developing national lists, before beginning any importation or 
manufacturing strategies, each medicine listed on the EML should be evaluated for existing 
patent protection. Patent protection for medicines can limit the availability of medicines on the 
EML within certain jurisdictions and therefore may require interaction with pharmaceutical 
manufacturers for importation or manufacture of qualified generics within these regions.  
 Recently, the biggest concern has been access to HIV/AIDS medications within the poorest 
of African countries.39 Essential medicines are listed in the EML as cost-effective solutions for 
individuals and countries to promote healthcare options that cultivate healthy populations. As 
early as 2001, HIV/AIDS antiretrovirals (ARV) were analyzed to determine the extent of patent 
coverage and the possible impact on impeding access to patent protected medications.40 
While the results of such studies were met with much controversy, an initial methodology was 
developed that was later expanded to analyze the entire WHO EML list in 2004.41  
 In 2004, the 13th edition of the EML was evaluated for the extent of products listed on the 
list that had existing patent coverage.42 The list was initially evaluated to identify generic 
therapies, defined as products that were considered “ancient or nonpharmacological” or had 
descriptions that did not correspond to a singly patentable product.43 These products were 
removed from the list due to the likelihood of expired or non-existent patent protection. The 
remaining products were then subjected to searches using printed and electronic databases to 
determine “basic patents” for each product, where the basic patent was considered to be the 
earliest identified patent covering either the active pharmaceutical ingredient or method of 
use.44  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  36	  Id.	  37	  Id.	  38	  Id.	  39	  Attaran,	  Amir;	  Gillespie-­‐White,	  Lee.	  “Do	  Patents	  for	  Antiretroviral	  Drugs	  Constrain	  Access	  to	  AIDS	  Treatment	  in	  Africa?”	  JAMA,	  286(15),	  1886-­‐92,	  2001.	  40	  Id.	  41	  Id.;	  Editorial	  Remarks	  to	  Attaran	  &	  Gillespie.	  JAMA,	  287(7),	  840-­‐43,	  2002.	  42	  Attaran,	  Amir.	  “How	  Do	  Patents	  and	  Economic	  Policies	  Affect	  Access	  to	  Essential	  Medicines	  in	  Developing	  Countries?”	  Health	  Affairs,	  23(3),	  155-­‐66,	  2003.	  43	  Id.	  44	  Id.	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 Once the initial patent searches were finished, the assignees for each basic patent were 
compiled.45 Surveys were then issued to each of the assignees listed on the patents to 
supplant omissions inherently found in patent databases.46 In the surveys, each assignee was 
asked for a disclosure of current patents and pending applications that covered WHO EML 
specified doses. The majority of companies responded with information to the queries, 
providing information regarding current patent coverage for the list of medicines.  
 Ultimately, and in line with previous analyses, approximately 6% of the list had at least one 
unexpired basic patent (19 of 319 products).47 Most of the products having existing patent 
coverage were ARV medications for HIV/AIDS that could limit importation and manufacture into 
developing nations depending on the patent status of medicines in these jurisdictions. 
Because they provide an information base for making rational and informed strategic 
determinations, analyses like this are a necessity to facilitate access to quality medicines in all 
nations. This study suggested that even in the face of highly complex and costly 
pharmaceutical development, many medicines on the EML that are essential to promoting 
global health appear to be unprotected by patents. 
The Orange Book 
Purpose of the Orange Book 
 The publication Approved Medicine Products with Therapeutic Equivalence Evaluation is 
commonly known as the Orange Book. The purpose of the Orange Book is to list all the 
medicine products approved through New Medicine Applications (NDAs) and Abbreviated New 
Medicine Applications (ANDAs), by the United States Food and Drug Administration (FDA) on 
the basis of safety and effectiveness, in a single place.48 State health agencies, prescribers, 
and pharmacists use the Orange Book to help make medicine product selection decisions.49 In 
practice, the Orange Book allows prescribers and pharmacists to make generic medicine 
substitutions for brand name medicines, or reference medicine products, by providing 
therapeutic equivalence evaluations of each approved prescription medicine product.50 By 
encouraging medicine product substitutions, the FDA seeks to contain healthcare costs.51 
History 
 By the late 1970s, the FDA struggled to meet the requests of individual states asking for 
assistance in preparing medicine equivalence lists.52 The FDA distributed the first embodiment 
of the Orange Book in January of 1979 as an attempt to solve this administrative issue.53 The 
list, officially known as the list of Approved Medicine Products with Therapeutic Equivalence 
Evaluations, included currently marketed FDA approved prescription medicines.54 The official 
policy for therapeutic equivalence evaluation can be found in the Federal Register.55 Generally, 
a pharmaceutically equivalent medicine product is an FDA approved medicine that has no 
known or suspected bioequivalence issues, has been manufactured in accordance with current 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  45	  Id.	  46	  Id.	  47	  Id.	  48	  U.S.	  Dept.	  of	  Health	  &	  Human	  Servs.,	  Approved	  Medicine	  Products	  with	  Therapeutic	  Equivalence	  Evaluations	  i	  (30th	  ed.	  2010).	  49	  Id.	  50	  Id.	  51	  Id.	  52	  Id.	  53	  Id.	  54	  Id.	  55	  See	  Therapeutically	  Equivalent	  Medicines;	  Availability	  of	  List,	  45	  Fed.	  Reg.	  72582	  (Oct.	  31,	  1980).	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good manufacturing practices, and meets necessary standards.56 A final version of the list was 
published in October of 1980.57 The FDA used the Orange Book to fulfill the 1984 Medicine 
Price Competition and Patent Term Restoration Act’s requirement to make a list of approved 
medicine products publicly available.58 
What Patents Are Included in the Orange Book 
 Anyone who submits an NDA, an NDA amendment, an ANDA, or a supplement to an 
approved medicine application must submit patent information to the FDA.59 The types of 
patents required for reporting include medicine substance (active ingredient) patents when the 
subject of the patent is the same as the subject of the application or the same as the active 
ingredient in the application.60 Patents claiming a polymorph of a reference compound can be 
reported if sufficient testing information is submitted proving that the polymorph is 
bioequivalent to the reference compound.61 Additionally, the formulation, composition, and 
method-of-use patents for the medicine in the application must be reported.62 Also, any 
patented change regarding a medicine’s method of use, submitted in supplements to the 
approved medicine applications, must be reported. For example, patents regarding a change 
in formulation, addition of a new indication or condition of use, or a change of strength, are 
required to be submitted in supplements.63 
What Patents Are Not Included in the Orange Book 
 The FDA does not require submission of information regarding process patents or patents 
claiming packaging, metabolites, or intermediates.64 Additionally, the Orange Book does not 
include patent information regarding medicines approved strictly on the basis of safety or 
medicines available prior to 1938.65 
Exclusivities 
 Exclusivity, in the United States, is an exclusive marketing right granted by the FDA upon 
approval of a medicine product and is different from Patent Term Extension (PTE) as provided 
for in 35 U.S.C. § 156.66 Exclusivities are statutory provisions and are granted to NDA 
applicants if the statutory requirements are met.67 Exclusivities are distinct and different from 
rights granted by patents and can run concurrently with a patent.68 For example, if both a 
patent and a granted exclusivity protect a particular medicine compound, and the patent is 
invalidated through litigation, the exclusivity will still provide the medicine protection, or 
exclusive marketing rights, for the duration of the exclusivity period. Some medicines have 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  56	  Id.	  at	  72600.	  57	  U.S.	  Dept.	  of	  Health	  &	  Human	  Servs.,	  supra,	  at	  i-­‐ii.	  58	  Id.	  at	  ii.	  59	  21	  C.F.R.	  §	  314.53	  (2009).	  60	  Id.	  61	  See	  21	  C.F.R.	  §	  314.53(b)(2)	  (discussing	  the	  requirements	  for	  submitting	  polymorph	  patent	  information).	  62	  21	  C.F.R.	  §	  314.53	  (2009).	  63	  Id.	  64	  Id.	  65	  Id.	  66	  http://www.fda.gov/Medicines/DevelopmentApprovalProcess/ucm079031.htm	  (Accessed	  Oct.	  1,	  2010)	  [hereinafter	  Frequently	  asked	  Questions	  on	  Patents	  and	  Exclusivity].;	  See	  35	  U.S.C.	  §	  156	  (PTE	  actually	  extends	  the	  term	  of	  the	  patent	  whereas	  exclusivity	  does	  not).	  67	  See	  21	  C.F.R.	  §	  314.108	  (1994);	  21	  C.F.R.	  §	  316.31	  (1997);	  21	  C.F.R.	  §	  316.34	  (1997).	  68	  Frequently	  asked	  Questions	  on	  Patents	  and	  Exclusivity,	  supra.	  note	  20.	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both patent and exclusivity protection while others have just one type or no protection.69 There 
are 5 types of exclusivities:  
• Orphan Medicine Exclusivity (ODE) which grants a 7-year exclusivity,  
• New Chemical Exclusivity (NCE) which grants a 5-year exclusivity,  
• Pediatric Exclusivity (PED) which grants a 6 month exclusivity, and  
• “Other” Exclusivity that grants a 3-year exclusivity for a “change” if 
criteria are met.70 One example of this “Other” Exclusivity is if an NDA 
applicant submits a supplemental application to the FDA that contains 
reports of clinical investigations, unrelated to bioavailability studies, 
which were essential to the supplemental application’s approval.71 
• Patent Challenge Exclusivity (PC) which grants 180 days of exclusivity to 
the first ANDA applicant, or generic medicine manufacturer, to file a 
“Paragraph IV” challenge to a NDA applicant’s patents for a particular 
medicine product listed in the Orange Book.72 An ANDA applicant’s 
“Paragraph IV” challenge to an Orange Book patent generally leads to 
patent litigation involving the challenged patent. 
Patent Use Codes 
 Patent use codes (PUCs) are listed in the Orange Book with the format being a number and 
a descriptor.73 The purpose of the PUC is to designate a code for a patent that covers the 
approved indication or use of a medicine product.74 It is important to note that the NDA 
applicants provide the FDA with the exact patent use code description to be published in the 
Orange Book.75 The FDA has no role in determining the appropriateness of patent use codes 
assigned to particular medicine products by NDA applicants.76 
Potential Issues with Patents Listed in the Orange Book 
 NDA applicants are solely responsible for submitting appropriate patent information to the 
FDA. Currently, NDA applicants are required to submit patent information as part of the NDA 
application process.77 That patent information, exactly as submitted by the NDA applicant, is 
then listed in the Orange Book.78 Although NDA applicants are required to submit specific 
patent information as part of the NDA application process, it is possible that NDA applicants 
may strategically choose to include some patent information initially and include other patent 
information at a later date.79 This strategy could potentially delay the entry of a bioequivalent 
generic medicine product into the market and prevent generic competition. The FDA, however, 
maintains a purely ministerial role regarding the listing of patent information submitted by NDA 
applicants.80 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  69	  Id.	  (follow	  “Why	  does	  the	  exclusivity	  expire	  before	  the	  patent?”	  hyperlink).	  70	  Id.	  (follow	  “How	  long	  is	  exclusivity	  granted	  for?”	  hyperlink).	  71	  See	  21	  C.F.R.	  §	  314.108	  (1994).	  72	  Frequently	  asked	  Questions	  on	  Patents	  and	  Exclusivity,	  supra.	  note	  20.	  73	  See	  http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm	  (Accessed	  Oct.	  1,	  2010).	  74	  See	  21	  C.F.R.	  §	  314.53	  (providing	  that	  a	  NDA	  applicant	  is	  required	  to	  provide	  a	  description	  for	  each	  method	  of	  use	  patent).	  75	  Id.	  76	  See	  Applications	  for	  FDA	  Approval	  to	  Market	  a	  New	  Medicine:	  Patent	  Submission	  and	  Listing	  Requirements	  and	  Application	  of	  30-­‐Month	  Stays	  on	  Approval	  of	  Abbreviated	  New	  Medicine	  Applications	  Certifying	  That	  a	  Patent	  Claiming	  a	  Medicine	  Is	  Invalid	  or	  Will	  Not	  Be	  Infringed,	  68	  Fed.	  Reg.	  36,676,	  at	  36,682-­‐83	  (June	  18,	  2003)	  (to	  be	  codified	  at	  21	  C.F.R.	  pt.	  314).	  77	  21	  C.F.R.	  §	  314.53.	  78	  Id.	  79	  See	  68	  Fed.	  Reg.	  36,373	  at	  36,683.	  80	  Id.	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 No administrative process exists for evaluating patent information submitted by NDA 
applicants. As mentioned, the NDA applicant is solely responsible for determining what patents 
should be included in the NDA application and, ultimately, what patents will be listed in the 
Orange Book. Currently, the FDA does not have the authority to declare any patent submitted 
by a NDA applicant invalid.81 The FDA’s position is that questions regarding the issuance and 
validity of patents are left to the USPTO and the courts.82  
 No administrative process exists for challenging patent listings or for seeking removal of 
patents listed in the Orange Book. Once a patent expires, it is no longer included in the Orange 
Book.83 Other than waiting for a patent to expire, generic medicine manufacturers have no 
other way, outside of invalidating a patent through litigation, to get a potentially improperly 
listed patent removed from the Orange Book. Because there is currently no administrative 
procedure for challenging patent listings, a fear exists that NDA applicants could submit 
inappropriate patent information to the FDA to delay generic competition.84 The FDA’s position 
is that the current system sufficiently addresses this concern because NDA applicants are 
required to submit specific detailed information regarding a medicine product’s patents and 
are required to certify that the information is correct.85 The FDA will relay questions about the 
accuracy of a patent submission to the NDA holder, but will not perform its own investigation.86 
Conclusion 
 The Orange Book, in addition to being a valuable tool utilized by health care providers 
making decisions about whether or not a specific medicine is therapeutically equivalent to a 
reference medicine product, lists patent information for medicine products approved and 
marketed in the United States. Although the possibility exists that all the patents relating to a 
specific medicine product will not be listed in the Orange Book, it can be a good starting point 
for finding relevant patents relating to specific medicine products in the United States. While 
the patents listed for a specific medicine product in the Orange Book cannot answer the 
broader question, i.e., if a specific medicine product is under patent in a specific jurisdiction 
outside of the United States, the patent information one obtains in the Orange Book, for 
example key words and/or INPADOC family data, can be used to facilitate a jurisdiction 
specific patent search. 
Patent Families 
Background 
 A patent family in its simplest form is a collection of patents from different jurisdictions that 
share a priority date with a single parent document. The concept for a patent family first 
emerged from the Paris Convention for the Protection of Industrial Property in 1883, which 
recognized the need to systematically analyze patents in different jurisdictions.87 When filing 
patent applications in multiple jurisdictions, an inventor must follow the individual procedures 
of each jurisdiction.88 Without patent families, searches are complicated because the multiple 
different jurisdictional applications are shown as independent results, making quick viewing 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  81	  Id.	  at	  36,684-­‐85.	  82	  Id.	  at	  36,685.	  83	  Frequently	  asked	  Questions	  on	  Patents	  and	  Exclusivity,	  supra.	  note	  20.	  84	  See	  Id.	  at	  36,683.	  85	  Id.	  86	  Id.	  at	  36,684.	  87	  Paris	  Convention	  for	  the	  Protection	  of	  Industrial	  Property	  art.	  4	  (A1-­‐A3),	  Mar.	  20,	  1883,	  13	  U.S.T.	  1,	  828	  U.N.T.S.	  107	  as	  revised	  at	  the	  Stockholm	  Revision	  Conference,	  July	  14,	  1967,	  21	  U.S.T.	  1538,	  828	  U.N.T.S.	  305.	  88	  Patent	  Law	  Treaty	  art	  5,	  S.	  Jun.	  1,	  2000,	  Treaty	  Doc.	  No.	  109-­‐12,	  2000	  WL	  35456908.	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and analysis of the patent landscape confusing and difficult. Therefore, using patent families 
eliminates the multiplicity of foreign and domestic filings when searching for patents, because 
a single representative member will be displayed in the results and all foreign filings of the 
same invention will be displayed in an organized, easy to read format. 
 However, while solving difficulties with multiplicity while searching, patent families are not 
infallible. Currently there is no single convention for defining a patent family.89 Thus different 
patent family generating services create families using different strategies. Due to the lack of a 
single convention, to ensure complete coverage, it may be necessary to search multiple 
sources of patent families. 
Importance 
 The rapid development of search technology has greatly advanced the capability of 
researchers to find patents. However, without an organized system categorizing patent activity, 
even the best searches quickly become unmanageable. The importance of patent families lies 
in the indexing of multiple patents, consequently showing global patent activity in a fairly 
straightforward and more manageable system.90 Because patent families show global activity 
of an invention, corporations can detail factors like marketing strategies in a multitude of 
jurisdictions.  
Types of Patent Families 
 The World Intellectual Property Organization (WIPO) defines patent families as a collection 
of patent documents sharing a common aspect that are published at different times in different 
jurisdictions.91 The patents all share priority to an originating member of the family. However, 
because priority rights of patents are not always linear relationships, different types of patent 
families exist to cope with the multitude of different priority relationships.92 WIPO has defined 
six patent family types that describe all potential priority relationships:93  
• Simple Patent Families 
• Complex Patent Families 
• Extended Patent Families 
• National Patent Families 
• Domestic Patent Families 
• Artificial Patent Families.  
 
The first five families are considered natural families since the members all share a true priority 
with one another.  
 Of the natural families, the simple, complex, and extended families are the most commonly 
used family priority schemes and grow in complexity from simple families to extended 
families.94 The simple patent family is the most basic of the patent families. In a simple patent 
family, all members of the family have the same priority to exactly the same originating 
application(s) (Figure 1).95 The simple family classification, while being the most straightforward 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  89	  EUROPEAN	  PATENT	  OFFICE.	  http://www.epo.org/patents/patent-­‐information/about/families.html.	  (last	  visited	  Dec.	  29,	  2010).	  90	  Id.	  91	  WIPO	  HANDBOOK	  ON	  INDUSTRIAL	  PROPERTY	  INFORMATION	  AND	  DOCUMENTATION,	  GLOSSARY	  OF	  TERMS	  CONCERNING	  INDUSTRIAL	  PROPERTY	  INFORMATION	  AND	  DOCUMENTATION	  Section	  8.1.1,	  8.1.18-­‐8.1.19	  (2008).	  92	  WIPO	  HANDBOOK,	  supra	  8.1.18.	  93	  WIPO	  HANDBOOK,	  supra	  8.1.19.	  94	  WIPO	  HANDBOOK,	  supra	  8.1.19.	  95	  WIPO	  HANDBOOK,	  supra	  8.1.19;	  Tom	  Wolf,	  PIUG	  Knowledge	  Base	  Page	  on	  Patent	  Families,	  (Dec.	  13,	  2007,	  12:20	  PM),	  http://wiki.piug.org/display/PIUG/Patent+Families.	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application of the family concept, also is the least informative of the patent landscape as it 
relates directly to a single originating document that all the family members share. 
 
 
Figure 1:	  Simple Patent Families. In purple, Family 1 consists of Document 1 only. In navy blue, Family 2 consists 
of Document 2. In light blue, Family 3 consists of Document 3. Lastly, in Green, Family 4 consists of Document 4. 
Here, though some documents have shared priorities (i.e. Document 1 and Document 2 share Priority 1), Document 
2 has an additional priority, Priority 2. Thus Document 2 is in a different Simple Family than Document 1 because the 
priority data does not match exactly between the documents.	  
 Complex families expand family data to include all the members of the family related to the 
same invention or inventions sharing common aspects.96 Each family member has at least one 
priority document in common with each other (Figure 2).97 Thus complex families provide a 
broader perspective of the patent landscape than simple families but are still limited in their 
capacity to provide complete patent family analysis.  
 
Figure 2: Complex Patent Families. Complex patent families extend the family members to documents having a 
shared priority document. Here, Family 1 consists of Document 1 and Document 2 because of shared Priority 1. 
Family 2 consist of Document 2 and Document 3 because of shared Priority 2. Family 3 consists of Document 3 and 
Document 4 because of shared Priority 3. 

























Family 1 Family 2 Family 3
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 Extended families are the broadest of the non-artificial patent families and are commonly 
used by patent searchers for priority searches. In an extended patent family, all members of 
the family relate to one or more inventions, and each member has at least one originating 
application in common with another member of the family.98 The difference between the 
extended patent family and the complex patent family is that each patent in an extended family 
need not relate to the same invention or even to inventions that share common aspects.  
 
 
Figure 3: Extended Patent Families. All of the priority documents are in the same family because they all share at 
least a one priority with all the other documents. Document 1 shares Priority 1 with Document 2. Document 2 shares 
Priority 2 with Document 3. Document 4 shares Priority 3 with Document 3. All the documents are in the same family 
because priority can be traced back to Priority 1. 
 The national patent family and domestic patent family refer to patents generated from the 
same office. In a national patent family, the members must be distinct from each other and 
have priority to at least one originating application in common with the family.99 The 
relationship between family members in a national patent family exists because of additions, 
continuations, continuations-in-part, or divisions of the parent application. In contrast to a 
national patent family, a domestic patent family member originates from a single office’s 
different procedural publications for the same parent application. 
 The last and broadest patent family is the artificial patent family.100 Artificial families are 
created by categorizing equivalent disclosures and matching documents that, while sharing 
common aspects, do not share priority to originating application(s) in the family.101 Artificial 
families therefore expand families far beyond the original priority data for natural patent 
families. The features of artificial families are value-added because artificial families provide 
more in depth analysis of patent relationships.102 
 Generating patent family data differs substantially, depending on the search parameters 
used and the construction of the families from the search service used. There are currently 
three primary family building services available, INPADOC, DWPI, and the TotalPatent™ 
families from LexisNexis®. 
INPADOC 
 International Patent Document (INPADOC) families are of the extended family type. They 
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World Patent Organization.103 INPADOC was incorporated into the European Patent Office 
(EPO) in 1989 and is now incorporated into the EPO’s European Patent Information and 
Documentation Systems Directorate (EPIDSD).104  
 INPADOC families were created in the infancy of patent families and thus were designed to 
be very broad to encompass a large amount of family data.105 As a consequence of its breadth, 
and because the members in each family need only share at least one priority document with 
at least one patent in the family, INPADOC families can become quite large. Large INPADOC 
families are especially prevalent in the chemical and biological arts.106 Recently, INPADOC has 
integrated older patent documents into the family system to create artificial families, 
sometimes showing family members back to the 1830s. These artificial families provide a 
source of searching for remotely extended family members that would be lost before the 
integration of family data. 
DWPI 
 The Derwent World Patent Index (DWPI) families are of the artificial family type. The system 
was developed in 1951 to facilitate quicker prior art searches for the chemical and 
pharmaceutical arts.107 DWPI differs substantially from other patent family systems because 
human intervention forms artificial families through codes, rewritten abstracts, and rewritten 
titles. Because of labor intensive rewriting and indexing, DWPI costs are substantially higher 
than INPADOC and are value-added.108  
 It is important to understand how DWPI divides patent priority data to understand family 
structure. DWPI divides data in basic records, those patents that appear to have unique priority 
data, and conventional equivalents, patents that share priority with the basic record. Together, 
the basic and conventional equivalent patents create simple patent families.109 However 
because of the value-added features of DWPI, such as rewritten abstracts and rewritten titles, 
patents that share subject matter or applicants can be added to pre-established patent 
families. These additional unrelated patents are termed non-equivalents and under normal 
family schemes cannot be included in any natural patent family because they lack the 
necessary priority. By combining non-equivalent patents with pre-established families, DWPI 
creates artificial families that extend patent data to a useful, more expansive view of patent 
activity. DWPI families are typically smaller than INPADOC families with some, but not 
complete, overlap. 
LexisNexis® TotalPatent™ 
 TotalPatent™ is a tool developed by LexisNexis® for patent searching that extends country 
coverage beyond that of INPADOC. TotalPatent™ families are generated using only priority 
information matching and do not include artificial family members. TotalPatent™ currently has 
three primary family generation strategies: Main Families, INPADOC Families, and Extended 
Families.110 TotalPatent™ Main Families are simple families generated with single priorities 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  103	  EUROPEAN	  PATENT	  OFFICE.	  http://www.epo.org/patents/patent-­‐information/about/families.html	  (last	  visited	  Dec.	  1,	  2010).	  104	  supra.	  105	  supra.	  106	  supra.	  107	  DERWENT	  WORLD	  PATENTS	  INDEX.	  DERWENT	  WORLD	  PATENTS	  INDEX	  EXTENSION	  –	  Bluesheets	  File	  280,	  http://library.dialog.com/bluesheets/html/bl0351.html	  (last	  visited	  Dec	  1,	  2010).	  108	  Derwent	  World	  Patents	  Index	  Bluesheets	  File	  280,	  supra	  “File	  Description”;	  DWPI	  REFERENCE	  MANUAL,	  supra	  7.	  http://thomsonreuters.com/products_services/legal/legal_products/intellectual_property/dwpi/	  (last	  visited	  Dec	  3,	  2010).	  109	  Derwent	  World	  Patents	  Index	  Bluesheets	  File	  280,	  supra	  “File	  Description”.	  110	  E-­‐mail	  from	  Jonathan	  Grant,	  LexisNexis	  Global	  IP	  Education	  Specialist	  Manager,	  to	  Dr.	  Kevin	  Clark	  (Nov.	  8,	  2010,	  8:26	  EST)	  (on	  file	  with	  receiver).	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between family members to the exact same originating document (see Figure 1). TotalPatent™ 
Main Families have single priority to a parent member and therefore provide the least amount 
of family information of the three TotalPatent™ strategies.111 
 The remaining two strategies, the INPADOC and Extended families are of the extended 
family type. Both families have at least one priority document in common with each other. 
However, the families differ in two keys ways. First, while both are of the extended family type, 
the Extended family strategy of TotalPatent™ has additional country coverage beyond that 
reported by INPADOC.112 Therefore, TotalPatent™ Extended families provide a broader 
coverage of filings in jurisdictions not found in any other family generating service. The 
INPADOC TotalPatent™ Family mirrors the methodology provided by INPADOC but excludes 
and members generated through human intervention.113 Second, while the TotalPatent™ 
Extended families broaden country coverage, TotalPatent™ currently provides no legal status 
for those members. In contrast, while the TotalPatent™ INPADOC family has fewer members, 
the reported INPADOC legal status is available but still excludes any priority generated through 
human intervention.  
Conclusions 
 While various strategies exist to generate patent families, it is readily apparent that each 
strategy has advantages and disadvantages, which must be weighed and analyzed to 
determine which service to use. No single service or combination thereof can guarantee finding 
every potential patent available for a given invention. Therefore, an experienced attorney 
should perform as in-depth search as possible with the resources available and seek additional 
help from offices on a jurisdiction-by-jurisdiction basis to mitigate concerns about prior art. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  111	  Id.	  112	  Id.	  113	  Id.	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How to Use This Report 
Division of Data 
 This report is designed as a layered approach to identify patents for a subset of medicines 
listed in the EML. By layering the data into successively more in-depth analyses, a user can 
quickly and efficiently locate pertinent information. However, it should be duly noted that this 
report is not a Freedom-to-Operate analysis nor is it fully comprehensive to the availability of 
patent data outside current standardized patent databases. The data is limited to patents and 
patent families having at least one US patent document and are current as of late 2010, and 
new data may well be available since that time. The data is further limited by the inherent 
limitations of the FDA Orange Book as described in the Orange Book Section. Thus, medicines 
lacking a US document may be missing patent documents that cover the medicine. Because 
no analysis can fully cover all available patent data in non-reporting jurisdictions, or 
jurisdictions that report infrequently, it is necessary for the user to verify the reported data in 
jurisdictions outside those reported by many electronic patent resources. Therefore, individuals 
should seek patent professionals in jurisdictions of interest to search national patent libraries 
and investigate regional patent offices.  
 The least in-depth of the analyses in this report is the Quick Reference Data Sheets, the 
printed sheets provided in the results section for each medication searched. Designed as a 
cursory overview, this data presents an encapsulated view of what the EML medicine is and its 
intended use, together with relevant patent information such as the presence or absence of a 
base patent, basic filing information, and available globe filing trends through generation of 
family data. The ITTI Clinic defines the base patent as the earliest identified patent covering 
either the active pharmaceutical ingredient or method of use. A total of 240 patents are found 
within the Quick Reference Data Sheets. These 240 patents represent the identified base 
patents (88) and Orange Book patents (152) without removing redundancies. Redundancies 
were not removed to represent the entire patent information identified for each medicine’s base 
patent(s) and Orange Book patent(s). 
  
Quick Reference Data Sheets 
Include: 
• Medicine name, Dose, and/or formulation, and Uses 
• Chemical name, Abstract number, and Formula 
• Base Patent information, including: Patent number, Original and Current 
assignee and country, and the Date filed 
• Orange Book Patent information, including: Patent number, Original and 
Current assignee and country, and the Date filed 
• A world map showing patent trends for patents, including: Patents having 
filing dates prior to 1980, Patents having filing dates between 1980-1989, 
and Patents having filing dates after 1990. 
 
***For quick reference purposes and for ease of use, the Quick Reference Data 
sheets are printed within this report and have been arranged in alphabetical order by 
medicine name. 
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 Because the intent of the WHO EML is to provide recommendations globally for national 
lists, locating patent family members was necessary to illustrate patent trends in jurisdictions 
outside the United States. Therefore, all ascertained base patents and patents located in the 
FDA Orange Book were subjected to searches to generate families using Derwent, INPADOC, 
and Lexis TotalPatent™. A total of 27,568 patents, including the base patents and Orange 
Book patents are listed in the Family Data Sheet. However, to reduce data redundancies in the 
family data, redundant Base Patents and Orange Book patents were removed before 
generating the family patent data. The Family Data Sheets present all the available generated 
family data and users can utilize this data to help analyze global patent trends for a particular 
EML medicine (DVD Electronic File Name: WHO_EML_Family Data.xlsx).  
 The third and most comprehensive of the spreadsheets is the Master Patent Data Sheet 
(DVD Electronic File Name: WHO_EML_Master Patent Data.xlsx. This spreadsheet contains all 
patent information extracted from Thompson Reuters Innovation (including all of the Base 
Patents and Orange Book Patents) and represents what may be useful patent information for 
the user of this report by providing all available information of Thompson Reuters in a single 
spreadsheet. This spreadsheet contains 166 unique patent documents derived from removing 
















Family Data Sheets 
Include: 
• Medicine name 
• Base Patent number 
• Orange Book patent number 
• Derwent World Patent Index (DWPI) family members 
• INPADOC family members 
• LexisNexis® TotalPatentTM family members 
 
***For quick reference purposes, the Family Data Sheets are placed in an electronic 
spreadsheet available on DVD (Electronic file name: WHO_EML_Family Data.xlsx) 
and have been arranged in alphabetical order by medicine name. 
Master Patent Data Sheet 
Includes: 
• Medicine name 
• Base Patent and Orange Book Patent information, including but not limited 
to: Application data, Publication data, priority data, family data, patent 
classification, and INPADOC legal status 
• Other patent information including but not limited to: Title, Abstract, Claims, 
Assignees, and Inventors 
• Hyperlinks to Adobe® pdf documents for all listed patents and patent 
applications 
 
***For quick reference purposes and for ease of use, the Master Patent Data Sheet is 
a single electronic spreadsheet available on DVD (Electronic file name: 
WHO_EML_Master Patent Data.xlsx). 
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 Together, the three data sheets provide a comprehensive overview of the current known 
status for each EML listed medicine provided by WHO. By providing layers of data, the user 
can quickly and efficiently find desired pertinent information for the task at hand by 
systematically providing increasingly complex layers of information in the successive data 
sheets. Refer to Figure 9 page 28 for a flowchart diagram of how each set of data is related. 
Application to Global Maps 
 The identified base patents for each medicine were reduced to the US patent when 
possible to simplify analysis. Using the family data, a series of global maps were created 
identifying patent filing trends. Countries colored in red show patent filings identified within the 
confines of the ITTI methodology that had filing dates from 1990 onward. Countries colored in 
orange show patent filings identified that had filing dates between 1980 and 1989. Countries 
colored in yellow show patent filings identified having a filing date prior to 1980.114 Countries 
colored in grey had no identified patent filings as defined by the confines of the methodology at 
any time. Though no patent filings were identified in these countries, this neither guarantees 
that no patent filings have been or are still valid within these jurisdictions nor does it alleviate 
users of this report from further investigation of these jurisdictions might be needed.  
 Important to note on the maps are the regional filing tables. Of particular interest are EPO 
filings. Members of the EPC who file regional patent applications must still undergo validity 
analysis in each designated jurisdiction before patent rights may be granted in each nation.115 
Thus while an EPO filing can cover all parties to the EPC, it is necessary for applicants to 
diligently pursue their rights in all nations.116 The importance of this necessity is shown in the 
apparent lack of patenting activity in France and Italy for example, for many of the products on 
the list having filing dates later than 1990. The EPO INPADOC legal status for these documents 
can be overwhelming and within the limited time frame for this project, it was simply impossible 
for student researchers to investigate each patent and application for all legal status. In 
addition, PCT national phase filings from France and Italy only proceed via the EPO. Thus, 
while some maps show no activity within European nations such as France and Italy, the 
presence of EPO filings corresponding to similar dates suggests with a high likelihood that 
regional filings exist and are patent databases are awaiting either prosecution of those filings or 
the prosecuted applications have yet to be reported. Therefore, to further investigate the status 
of any given patent in a EPO filing, additional research is necessary. 
 Limitations may also exist with the African regional offices, OAPI and ARIPO. However, the 
regional offices of these organizations work differently than the EPC. There are currently 16 
member states of OAPI: Benin, Cameroon, Central African Republic, Chad, Congo, Gabon, 
Cote d’Ivoire, Mauritania, Niger, Senegal, Republic of Togo, Burkina Faso, Guinea, Guinea-
Bissau, Mali, and Equatorial Guinea.117 Unlike the EPC where the applicant must seek 
verification within each designated member state, under OAPI, once the regional office grants 
a patent, the patent is immediately effective in all member states.118 Similarly, there are 
currently 16 member states of ARIPO: Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, 
Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Tanzania, Uganda, Zambia, 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  114	  The	  filing	  dates	  were	  determined	  from	  the	  latest	  filing	  date	  of	  the	  most	  recent	  family	  member	  115	  European	  Patent	  Convention	  art	  66,	  79.	  1973;	  PCT	  Applicant’s	  Guide	  –	  National	  Phase	  –	  National	  Chapter	  –	  European	  Patent	  Office.	  WIPO,	  Jan.	  14,	  2010.	  37	  Pages.	  116	  European	  Patent	  Convnetion	  art	  66,	  79.	  117	  PCT	  Applicant’s	  Guide	  –	  National	  Phase	  –	  National	  Chapter	  –	  Office	  of	  the	  African	  Regional	  Intellectual	  Property	  Organization	  (ARIPO).	  WIPO,	  Jan.	  14,	  2010.	  8	  Pages.	  118	  Id.	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and Zimbabwe.119 Similar to OAPI, under ARIPO, once the ARIPO office grants a patent, the 
patent is immediately effective in all member states.120 Thus, while both of these organizations 
provide for immediate patenting in each member state, both organizations still appear to lack 
the means to consistently report patents to international patent databases. 
Methods 
Comparative Approach Between ITTI and Former Methodologies 
 The previous approach developed by Attaran in 2004 was an effective methodology to 
evaluating existing patent coverage for medicines on the WHO EML.121 However, as with any 
methodology, limitations generate opportunities for further developments to create a better, 
more efficient system. When approached by the WIPO Global Strategies to create a new 
methodology, built upon the established system by Attaran, the ITTI Clinic sought three key 
elements. First, the methodology should serve as an educational model for member states to 
ascertain existing patent coverage. As an educational facility, FPCIP encourages innovative 
learning in the field of intellectual property and supports efforts to educate member states to 
develop their own capabilities. Second, the methodology should be cost-effective as member 
states may not have every conceivable resource available at their disposal. Lastly, the 
methodology should be reproducible and highly transferrable so member states can readily 
access and utilize data for their own purposes. With these goals in mind, the ITTI Clinic set out 
to adapt the Attaran methodology to reasonably meet these goals. 
 Generally, similar to the Attaran methodology, the ITTI Clinic first scanned a subset of the 
16th edition of the EML provided by WHO for products that were unlikely to have existing 
patent protection or were generalized therapies that likely had did not correspond to a single 
patentable product.122 Following the elimination of products meeting the above elements, the 
list was searched using the DTP. Briefly, and also similar to the Attaran approach, each 
medicine was subjected to searches using available patent databases and additional resources 
to determine a base patent.123 The ITTI definition of a base patent was the earliest identified 
patent covering either the active pharmaceutical ingredient or method of use. These patents 
were compiled and the medicines were subjected to additional searches using FDA online drug 
repository to identify additional patents reported to the FDA that covered the EML products. 
Once these patents were identified, each patent was subjected to an analysis of family 
members to generate a listing of patents covering each medicine globally. 
 The Attaran methodology continued after this point to send surveys to each of the 
assignees on all identified basic patents to obtain omissions inherent in the patent 
databases.124 The goal of the Attaran methodology, which was predominantly of an academic 
nature, was to identify, as comprehensively as possible, all existing patent coverage for EML 
products within the confines of the African continent.125 Among the conclusions arrived at, was 
the suggestion that patents were not an impedance to access to medicines within poorer 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  119	  PCT	  Applicant’s	  Guide	  –National	  Phase	  –	  National	  Chapter	  –	  African	  Intellectual	  Property	  Organization	  (OAPI).	  WIPO,	  Jan.	  14,	  2010.	  8	  Pages.	  120	  Id.	  121	  Attaran,	  Amir.	  “How	  Do	  Patents	  and	  Economic	  Policies	  Affect	  Access	  to	  Essential	  Medicines	  in	  Developing	  Countries?”	  Health	  Affairs,	  23(3),	  155-­‐66,	  2003.	  122	  Id.	  See	  Results	  section	  and	  Appendix	  B	  for	  complete	  table	  of	  the	  subset	  of	  medicines	  given	  to	  the	  ITTI	  Clinic.	  Includes	  updates	  to	  the	  EML	  between	  2003	  and	  2009.	  123	  Id.	  124	  Id.	  125	  Id.	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member states.126 In contrast, this report was designed as a research project to devise an initial 
protocol and methodology to instead create a methodology that member states could learn 
from and adapt for their needs. Thus the ITTI Clinic methodology provides patent trends rather 
than factual, discrete patent data. The trend data provides users with a broader view of both 
past and present patent activity for medicines on the EML, globally and not just within the 
confines of the African continent. Unlike in the Attaran methodology, here, no surveys were 
issued to assignees of identified patents; however, WHO as a future step in continuing this 
research may decide to issue such surveys. 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  126	  Id.	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Decision Tree Protocol 
 
Decision Tree Protocol - Explanation 
 The Decision Tree Protocol (DTP) was established to ascertain the base patent for each 
medicine using a systematic methodology. The ITTI Clinic defines a base patent as the earliest 
identified patent covering either the active pharmaceutical ingredient or method of use.  
 The first step in finding a base patent for a given medicine involved searching the online 
Orange Book database using either the “active ingredient” or the “proprietary name” search 
fields. The results of this search determined the extent of further research necessary. If active 
patents were found using the online Orange Book database, then those active patents were 
further explored within the United States Patent and Trademark Office (USPTO) Patent 
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application statuses, and includes domestic family information for a patent.127 The PAIR 
website provides additional patent information by including the relationship between patent 
documents (i.e. continuation, continuation in part, or divisional) along with priority information – 
information that was vital in confirming whether the base patent retrieved from the Orange 
Book database was most likely the earliest available patent. After researching the base patent 
with PAIR, the base patent was evaluated and the procedure and results documented. For 
further precision, the medicine was researched in the latest available Merck Index to provide a 
secondary verification of the base patent.  
 If no results were found in the initial Orange Book, or if only “unexpired patents”, as listed 
by the online Orange Book database, the Merck Index was searched. The Merck Index was 
also cross-checked for patents identified using the Orange Book database. If the medicine was 
located in the Merck Index with a listed base patent, then the name of the medicine, formula, 
CAS number, medicine code, brand name, synonyms and the base patent number were 
recorded. If additional derivatives of the medicine were listed in the Merck Index, the additional 
derivative information was also documented. After obtaining information from the Merck Index, 
PAIR was used to research domestic family information. All base patents retrieved from the 
Merck Index were redundantly searched in the online Orange Book and all results were 
documented. 
 If the medicine was listed in the Merck Index without base patent information, a United 
States Patent and Trademark Office (USPTO, http://www.uspto.gov) keyword search was 
performed using the searching capabilities of the USPTO website. If a base patent was located 
using search strings, the domestic family information was researched through the PAIR 
website to obtain priority information and redundantly checked through the online Orange 
Book database.  
 If a base patent is not found at this point, then the Bridge technique using ProQuest® 
DialogTM should be applied to the medicine (see Appendix C).128 The Bridge technique is an 
advanced patent searching technique in that uses searches across multiple DialogTM databases 
to pinpoint information. The ITTI Clinic used the Bridge technique, to focus on locating granted 
US patents only. If a base patent was found using the Bridge technique, then the base patent 
was researched on the PAIR website for domestic family information and subjected to a 
redundant check through the online Orange Book database. If no base patent was found using 
the Bridge technique, search options to locate a base patent were apparently exhausted, and 
search results were documented.  
 If the medicine was unlisted in the Merck Index, the WHO pre-qualification list for essential 
medicines was searched.129 The WHO pre-qualification of medicines is a list of medicines that 
have passed the quality, safety and efficacy standards of WHO.130 The DialogTM ChemSearch 
database was then searched using keywords obtained from the pre-qualification list to obtain 
CAS numbers, molecular formulas and synonyms of the essential medicine searched. The 
information was then crosschecked with the Merck Index, a USPTO search, and a search 
through the online Orange Book database as detailed above.  
 Combinational therapies (such as many ARV) were searched using the DTP for each 
component active ingredient and for patents covering the combination itself using the strategy 
detailed above. Following the DTP closely is not only vital in determining the base patent for a 
medicine, but is also vital to maintaining an accurate and systematic methodology of searching 
for base patents.  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  127	  http://portal.uspto.gov/external/portal/home.	  128	  See	  appendix	  C,	  explaining	  the	  Bridge	  technique	  in	  depth.	  129	  http://www.who.int/mediacentre/factsheets/fs278/en/index.html	  130	  Id.	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Orange Book Searches 
 Orange Book patents were found using the FDA online Orange Book data repository.131 The 
ITTI Clinic searched by prescription active ingredient, entering the essential medicine 
ingredient into the search field. This search would result in a listing of all FDA applications 
pertaining to the searched medicine. The ITTI Clinic searched each application, recording all 
patents listed for the searched essential medicine, taking note of WHO EML suggested 
dosages and formulations. The screenshots below illustrate an example search for Indinavir: 
 
 
Figure 4: The Orange Book homepage at the FDA website. 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  131	  http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm.	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Figure 5: Active Ingredient search page, with Prescription Medicine option highlighted. 
 
 
Figure 6: Search results for Indinavir, showing two FDA Orange Book applications. 
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Figure 7: Application page for Application number N020685, one of the two applications on the results page. Next 
ITTI Clinic members select the “View” link for Patent and Exclusivity info. 
 
 
Figure 8: Listed patent information for Indinavir for application N020685, showing no patents with FDA exclusivity. 
ITTI Clinic members would then perform the same sequence for all applications. 
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Patent Family Generation 
The ITTI Clinic collected family data for each base patent and Orange Book patent for the 
subset of medicine identified by WHO on the EML and provided to the ITTIC Clinic. Three sets 
of family data were created for each identified patent: 
• DWPI Family 
• INPADOC Family 
• TotalPatent Expanded Family 
 
 DWPI and INPADOC families were obtained using the Thomson Innovation patent 
database. Data for the TotalPatent Expanded Family came from the LexisNexis® TotalPatent 
database. The family patents were placed into an Excel® spreadsheet in a uniform format so 
that the data could be automatically reformatted into a grid using the ITTI designed Excel® 
macro as described subsequently, to create a grid that displays patent filings for each 
medicine or patent by respective country. 
Patent Family Data Spreadsheet Generation – Excel Macro Development 
 The preformatted set of base patent and Orange Book family data were reformatted into an 
x-y coordinate grid system with the x-coordinate corresponding to the essential medicine and 
the y-coordinate corresponding to nation of activity, using an automated macro (a script for 
automating activity in Microsoft Excel using the VisualBASIC programming language). 
 Multiple x-y co-ordinate grid systems were created to display world-wide patent trends for 
essential medicines and their individual patents. These grids are included in the DVD 
accompanying the report. 
 The preformatted columns of base patent and Orange Book family data were reformatted 
into an x-y coordinate grid system with the x-coordinate corresponding to either the essential 
medicine or its individual patents and the y-coordinate corresponding to the jurisdiction of 
activity. An automated macro (a script for automating activity in Microsoft Excel® using the 
VisualBASIC programming language) was developed to facilitate this sorting process. 	  
 First, a lookup table was created containing the name of each nation and its WIPO country 
code.132 Second, a grid was created containing the name of the essential medicine or the 
individual patent comprising the x-axis, and the individual nations comprising the y-axis was 
created. Third, for each column of family patent data in the preformatted sheet, the program 
looked up the country code prefix for that patent in the lookup table from Step (1) and placed 
that patent into the grid corresponding to the essential medicine or individual patent on the x-
axis and its country (determined through the lookup scheme) on the y-axis. If a patent already 
occupied the relevant cell, then the current patent was added after the first patent. The final 
value for each grid cell was the consolidated, de-duplicated data from the three family sources: 
DWPI, INPADOC, and TotalPatent™.  
 This process was repeated in further grids for which the patent inputs were limited to 
patents filed within specific time periods. One such set of grids was made for families created 
from base and orange book patents filed before January 1, 1980. Another set of grids was 
made based on patents filed between January 1, 1980 and December 31, 1989. A final set of 
grids was made based on patents filed on or after January 1, 1990. 
 Finally, the values in the x-y coordinate grid system were transformed from a list of patents 
to a four-value system. A value of “Y” (Yellow) for a medicine grid cell indicated the most the 
most recent patent document was filed before January 1, 1980. A value of “O” (Orange) for a 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  132	  See	  Appendix	  D	  for	  country	  coverage	  and	  codes	  of	  all	  countries	  in	  INPADOC,	  DWPI,	  and	  TotalPatent.	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medicine grid cell indicated the most recent patent document was filed between January 1, 
1980 and December 31, 1989. A value of “R” (Red) for a medicine grid cell indicated the most 
the most recent patent document was filed on or after January 1, 1990.    
 The values from this grid served as input data for the world map generation. 
World Map Generation 
 World maps were generated from patent family data using the MaplandTM Basic software 
package from Software Illustrated®. For each essential medicine a world map was generated 
indicating countries with a history of patent document filings. In addition, the world map 
employs yellow as corresponding to patent documents filed before 1980, orange 
corresponding to patent documents filed between 1980 and 1989, and red corresponding to 
patent documents filed after 1990. Overall patent trends having world maps use the identical 
color scheme to individual maps and were generated using the same software. 
Chemical Structure Generation 
 All chemical structures were ascertained from medicinal package inserts using provided 
International Union of Pure and Applied Chemistry (IUPAC) nomenclature. The structures were 
generated using Cambridgesoft® ChemdrawTM Ultra version 12.0 software package and 
verified for correct stereochemistry using built-in structure verification and cross-checked 
against structures provided in the package insert. 
Part I, Pages 1 - 50 Executive Summary, Introduction, Methods, Results, and Discussion Sections.
	   26	  
Results 
Medicines and Base Patents 
 A subset of 91 essential medicines added to the WHO EML since 2003 was assigned to the 
ITTI Clinic for analysis. (See Appendix Table A for the complete list of products from analyzed 
from the EML). Dr. Attaran had cleared much of this list in his 2003 study of the entire 13th 
Edition of the EML.133 Thus, building upon the work of Dr. Attaran, this subset consisted of the 
17 medicines identified in 2003 having existing patent protection and 74 medicines added to 
the EML since 2003.134 Similar to the previous strategy, products on the EML with high 
probability of non-existing patent protection and products that did not correspond to a singly 
patentable product were removed from the analysis: thirteen such products were removed 
from the list.135 These products included: Cholera, haemophilus influenxae type B, hepatitis A, 
Japanese encephalitis, pneumococcal, rotavirus, and varicella vaccines, human 
immunoglobulin, nicotine gum, oral rehydration therapy, surfactant, xylometazoline, and zinc 
sulfate. The remaining products (78) were subjected to the searches using the Decision Tree 
Protocol (DTP) methodology described herein to identify base patents.  
 
Table 1: Products identified as having existing base patent protection in the 2004 Attaran study.136 All of these 
medicines were again analyzed using the methodology described in this report. (Medicines in Red, according to the 
methodology used here, appear to no longer have active base patents) 






Efavirenz  Saquinavir 




 From the 78 analyzed products, 88 base patents were identified, where the base patent is 
considered as the earliest identified patent for the active pharmaceutical ingredient or method 
of use. Removing redundancies in the data yielded 70 unique base patents. Because many of 
these products have earlier patent filing dates, the ITTI team chose to use a cutoff date of 1990 
to identify products that might still have existing patent protection. Of the 70 unique identified 
base patents, 53 patents had filing dates prior to 1990 leaving 17 base patents having filing 
dates post January 1, 1990. These 17 patents constitute approximately 5% of the analyzed list, 
a value that is consistent with the previous results of Dr. Attaran’s research.137 Additionally, also 
like the previous study, the majority of products having existing patent protection were ARV 
medications for HIV/AIDS treatment.138  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  133	  Attaran,	  Amir.	  “How	  Do	  Patents	  and	  Economic	  Policies	  Affect	  Access	  to	  Essential	  Medicines	  in	  Developing	  Countries?”	  Health	  Affairs,	  23(3),	  155-­‐66,	  2003.	  134	  Id.	  135	  Id.	  136	  Id.	  137	  Id	  138	  Id.	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Table 2: Products with base patents filed after 1990. Lumefantrine appears to not have a US family member of 
the identified Chinese base patent. Abbreviations: EFV = Efavirenz, FTC = Emtricitabine, TDF = tenofovir disproxol 
fumarate, NVP = Nevirapine, d4T = Stavudine, 3TC = Lamuvidine 
Medicine Patent Document Medicine Patent Document 
Arthemether US5677331 Nevirapine(NVP) US5366972 
Atazanavir US5849911 Ritonavir US5541206 
Efavirenz(EFV) US5519021 Omeprazole US5693818 
EFV/FTC/TDF US20070099902A1 Saquinavir US5196438 
Emtricitabine(FTC) US5210085 Stavudine(d4T) US5130421 
FTC/TDF US20040224917A1 Tenofovir (TDF) US5922695 
Indinavir US5413999 3TC/NVP/d4T US20080241265A1 
Lopinavir US5914332 Nelfinavir US5484926 
Lumefantrine CN10425335   
 
 The ITTI Clinic searched the FDA Orange Book to provide additional details about existing 
patent coverage that could prohibit importation or manufacture. From the Orange book an 
additional set of 152 patents were identified, yielding a total of 166 unique patent documents. 
(Redundancies were identified between the base patents and patents located using the online 
Orange Book database. Removing the redundancies reduced the total number of patent 
documents to 166 unique documents from the originally located 222 documents). All of the 
base patent documents are listed as US documents when possible in this report to simplify the 
analysis.  
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Figure 9: Flowchart for Results and How the Data was Generated for this Report as described above. 91 total 
medicines were reduced to 78 after removing products that likely did not have existing patent coverage because of 
the age of the drug or because they were not singly patentable products. From the 78 investigated medicines, 70 
base patents and 152 orange book patents were obtained that were reduced to 166 unique documents after 
removing redundancies. The 166 unique documents were expanded using family data to 27568 patent documents. 
WHO Therapeutic Groups  
 It is also important to identify the number of patents in each WHO therapeutic group. By 
comparing the number of patents in each therapeutic group to total number of patents, a user 
of this report can quickly identify which groups may have patent protection. Tables 3 and 4 
compare the total number of patents to WHO therapeutic groups that have representative 
medicines in the subset provided by the WHO. As can be seen in both Table 3 and Table 4, the 
overwhelming numbers of patent documents lie within the anti-infective WHO therapeutic 
group. This group represents all of the ARVs along with any antibiotics and antifungal 
medications. Because the subset provided to the ITTI Clinic was not a full representation of the 
entire WHO EML not all therapeutic groups are represented in the table. The pie charts below 
each table are graphical representations of the data in each table. 
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Table 3: Patent Trends and Its Relation to WHO Therapeutic Groups – All Years. The number of patent is 
cumulative of all Base Patents (70), Orange Book Patents (152), and Patents identified via Family analysis (27,568). 




WHO Therapeutic Group Name Number of 
Patents 
2 Analgesic Medicines 54 
3 Antiallergic Medicines 1 
5 Anticonvulsant Medicines 160 
6 Anti-Infective Medicines 25099 
  6.2.1 Beta Lactam Medicines 399 
  6.2.2 Other Antibacterials 1394 
  6.2.4 Antituberculosis Medicines 271 
  6.3 Antifungal Agents 173 
  6.4.1 Antiherpes Medicines 1181 
  6.4.2.1 NARTI Inhibitors 3730 
  6.4.2.2 NNRTI Inhibitors 973 
  6.4.2.3 Protease Inhibitors 16167 
  6.4.3 Other Antivirals 168 
  6.5.2 Antileishmaniasis Medicines 275 
  6.5.3 AntiMalarial Medicines 268 
  6.5.4 Antipneumocystosis Medicines 3 
  6.5.5.1 African Trypanosmiasis 11 
8.2 Cytotoxic Medicines 86 
12 Cardiovascular Medicines 260 
17 Gastrointestinal Medicines 808 
18 Hormones and other Endocrine Medicines 77 
22.1 Oxytocics and Antioxytocics 215 
24.5 Psychoterapeutic Medicines 152 
25.1 Antiasthmatic Medicines 701 



























Number of Patents Per WHO Therapeutic Group - All Years!
Part I, Pages 1 - 50 Executive Summary, Introduction, Methods, Results, and Discussion Sections.
	   30	  
Table 4: Patent Trends and Its Relation to WHO Therapeutic Groups – Post 1990. The number of patent is 
cumulative of all Base Patents (70), Orange Book Patents (152), and Patents identified via Family analysis (27,568). 
WHO Therapeutic 
Group Number 
WHO Therapeutic Group Name Number of 
Patents 
2 Analgesic Medicinces 26 
3 Antiallergic Medicines 0 
5 Anticonvulsant Medicines 0 
6 Anti-Infective Medicines 26 
 6.2.1 Beta Lactam Medicines 0 
 6.2.2 Other Antibacterials 1165 
 6.2.4 Antituberculosis Medicines 39 
 6.3 Antifungal Agents 0 
 6.4.1 Antiherpes Medicines 707 
 6.4.2.1 NARTI Inhibitors 2107 
 6.4.2.2 NNRTI Inhibitors 973 
 6.4.2.3 Protease Inhibitors 15267 
 6.4.3 Other Antivirals 0 
 6.5.2 Antileishmaniasis Medicines 273 
 6.5.3 AntiMalarial Medicines 240 
 6.5.4 Antipneumocystosis Medicines 0 
 6.5.5.1 African Trypanosmiasis 0 
8.2 Cytotoxic Medicines 0 
12 Cardiovascular Medicines 161 
17 Gastrointestinal Medicines 685 
18 Hormones and other Endocrine Medicines 63 
22.1 Oxytocics and Antioxytocics 0 
24.5 Psychoterapeutic Medicines 43 
25.1 Antiasthmatic Medicines 598 
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WHO Regional Analysis  
 The WHO divides the Member States into 6 regions that are not the same as the United 
Nations designations. The regions individually develop strategies to control and prevent 
chronic and noncommunicable diseases. The regional division helps to reduce the overall 
burden on the WHO headquarters while also creating offices with more intimate knowledge 
and contact within each region. Because the regions are imperative to the WHO health mission 
to ensure that medicines on the EML satisfy the priority health care needs of the population, an 
analysis of potential patent protection for medicines on the list is crucial to understanding how 
innovators may develop patent strategies for new medications. 
 Tables 5 and 6 show the number medicines patented in each region. Because many 
medicines are patented in numerous countries within the same region, the numbers shown are 
much higher than the number of medicines listed in the subset. However, most important to 
the analysis is the average per country since this represents the overall impact patents for EML 
medicines may have for each region. As can be seen in Tables 5 and 6, the European region 
has the most patent document per country whereas the African region has the least. 
Surprisingly, the American region as the third highest average number demonstrating that only 
a two major countries, the US and Canada, are primary places for apply for patents. 
 
Table 5: Patent Filing Trends and Relations to WHO Regions – All Years. Data is cumulative of patent filings 
arising from Base Patents, Orange Book Patents, and Family Patents. The number of medicines represents the 
combined total number of patent filings in each country. A medicine patented in multiple countries was counted 










African Region 109 46 2 
American Region 245 35 7 
Eastern Mediterranean 
Region 50 21 2 
European Region 939 53 18 
South-East Asia Region 61 11 6 
Western Pacific Region 336 27 12 	  
Table 6: Patent Filing Trends and Relations to WHO Regions – Post 1990. Data is cumulative of patent filings 
arising from Base Patents, Orange Book Patents, and Family Patents. The number of medicines represents the 
combined total number of patent filings in each country. A medicine patented in multiple countries was counted 










African Region 59 46 1 
American Region 161 35 5 
Eastern Mediterranean 
Region 22 21 1 
European Region 624 53 12 
South-East Asia Region 81 11 7 
Western Pacific Region 276 27 10 	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Assignee Analysis  
 Which innovators are filing for patent protection is important to determine which companies 
need to be approached when making decisions regarding use or manufacture of EML 
medicines in certain jurisdictions. Figure 10 compares number of patents in relation to the top 
10 patenting companies. The top patenting companies have 10 or more patents with filing 
dates post 1990. As expected, the largest pharmaceutical companies also have the largest 
number of patents for medicines on the EML. 
Figure 10: Comparison of Assignee Companies. Assignees were determined from the 166 unique patent 
documents found on the Master Patent Spreadsheet. 
 
Patents and Country Income Analysis 
 Finally, it is important to understand the importance of national income in relation to the 
number of patents filed in differing income level countries. Traditionally, countries that have 
little resources and fall within the lower and low income WTO income brackets are less likely to 
be pursued by innovator companies for patent protection as the manufacturing capacity may 
not likely exist in these jurisdictions. As seen in Figures 10 and 11, regardless of the time frame 
looked at, nations classified by the WTO as high-income nations have significantly higher 
numbers of medicines on the EML protected by patents. In contrast, nations classified as low-
income nations, regardless of the time period analyzed, have very little numbers of medicines 
on the EML protected by patents. Such analysis suggests that procurement officers in 
countries with more wealth should more diligently investigate the patent status of medicines on 
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Figure 11: Essential Medicines and Their Relationship to World Bank National Income Levels – All Years. Data 
is cumulative of patent filings arising from Base Patents, Orange Book Patents, and Family Patents. The number of 
medicines represents the average of the combined total number of patent filings in each country (representative 
medicines in the graph are from a binary analysis. That is a 1 designates if any patent document is filed in a 
particular jurisdiction, thus counting the medicine as patented in that income level, and a 0 designates if no patent 
documents are filed in a particular jurisdiction). A medicine patented in multiple countries was counted a single time 




Figure 12: Essential Medicines and Their Relationship to World Bank National Income Levels – Post 1990. 
Data is cumulative of patent filings arising from Base Patents, Orange Book Patents, and Family Patents. The 
number of medicines represents the average of the combined total number of patent filings in each country 
(representative medicines in the graph are from a binary analysis. That is a 1 designates if any patent document is 
filed in a particular jurisdiction, thus counting the medicine as patented in that income level, and a 0 designates if no 
patent documents are filed in a particular jurisdiction). A medicine patented in multiple countries was counted a 
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Discussion and Conclusions 
 With respect to the subset of the WHO EML analyzed for patent coverage, this report 
represents a temporal continuation of the Attaran analysis in that it is based on his findings, 
accepting and incorporating these as a starting point and proceeding therefrom.139 Therefore, 
building on the analysis that Attaran undertook, this report analyzes what he identified as 
potentially/likely still under patent protection plus the additions to the EML since 2003. 
Nevertheless, while similar in some respects, the ITTI approach differed from that of the 
Attaran group in several key features. The ITTI goal was to develop a comprehensive yet 
readily transferrable methodology to identify patent filings for medications on the WHO EML, 
with a preliminary presentation of patent data to illustrate consistency with the previous Attaran 
study, robustness of the methodology and protocol and as a foundation for subsequent 
research, analyses and refinements. Somewhat in contrast, in the Attaran study, the overall 
goal was to assemble patent data in order to empirically test the policy presumption that 
patents are a primary block, particularly in developing countries, for access to medicines on 
the WHO EML. In this report, we provide, in addition to an update of the Attaran analysis, a 
more thorough pool of patent data and information and a methodically detailed protocol. Both 
of these value-added features can then be used and refined in subsequent iterations of the 
EML patent analysis project.  
 The aggregate findings presented in this report and those of the previous work of Attaran 
are not inconsistent:140 we estimate that approximately 5-6% of the 355 medicines on the WHO 
Essential Medicines List (EML) are still under patent (base patents for medicines), close to the 
Attaran estimate. It is important to note though, that this estimation is qualified, taking into 
account several assumptions that are outlined in the report. For example, ITTI was provided 
with a subset of the EML that followed the Attaran study, culling non-patented medicines and 
generating the group most likely to still be under patent; it was from this point that ITTI 
proceeded, reasonably relying on the integrity of this previous work. In addition, ITTI did not 
analyze the most recent updates to the EML, which became available in April 2011. It is also 
important to emphasize that solid research generally generates more questions than it 
answers, e.g., in this case, it would be interesting to know more about where, i.e., in which 
national jurisdictions, this subset of 5-6% are still under patent; that indeed is the challenge.  
 Although the data presented herein both builds on that of Dr. Attaran and supports his 
general conclusions, other aspects differ, in terms of methodology, presentation and 
availability of data, from this earlier work.141 Whereas the Attaran and ITTI methodologies both 
initially analyzed the EML medicines for patents via searching of patent database platforms, 
Attaran subsequently assembled patent data and then approach the various patent portfolio 
owners (assignees) in order to procure a more complete data set; this served to solidify and 
verify core data. ITTI, however, did not take this step, albeit it was discussed and considered 
as a possible future addition to the overall methodology and protocol developed. However, 
unlike Attaran, ITTI has presented a highly detailed protocol for analyzing patent information 
related to the WHO EML; this can serve as a tool for subsequent development as well as an 
educational template for building capacity in the member states, particularly the developing 
countries of Asia, Africa and Latin America. Furthermore, the Attaran study did not provide 
highly in depth patent data; however the ITTI report provides layers of data that can be 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  139	  Attaran,	  Amir.	  “How	  Do	  Patents	  and	  Economic	  Policies	  Affect	  Access	  to	  Essential	  Medicines	  in	  Developing	  Countries?”	  Health	  Affairs,	  23(3),	  155-­‐66,	  2003.	  140	  Id.	  141	  Id.	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accessed, mined, analyzed and thereby utilized for many purposes, from policy to strategy to 
implementation.  
 The results presented herein corroborate and support Attaran’s general conclusion that 
patents, per se, might not be the principal, or even the secondary, obstacles for developing 
country access to the WHO EML medicines (with the possible exception of anti-retroviral 
medicines in some jurisdictions).142 Perhaps there are other challenges conditioning global 
access that require more urgent attention, including, as Attaran pointed out, poverty.143 In 
addition, investment and capacity building in domestic R&D capabilities, production capacity, 
delivery, storage infrastructure, as well as technology transfer will certainly serve to create 
sustainable systems for WHO EML access and distribution. Finally, if patents indeed are not 
the principal obstacle, then perhaps patent information, when assembled and analyzed, will in 
fact facilitate strategic management of patents towards accelerating global access to the EML 
medicines. Hence, and perhaps paradoxically, patents might not be part of the problem but 
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